ESR1 and neoplasm: The eighth edition of the AJCC staging system introduced a new prognostic staging system that incorporates biomarkers such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status, and tumor grade [2].